Primary Care

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

In this expert interview, Deepak L. Bhatt, MD, MPH discusses guideline-based and emerging strategies for reducing recurrent ischemic stroke risk. From dietary interventions and blood pressure control to...

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.